Special Issue - Open for Citations

Non-Small Cell Lung Cancer Therapies

Message from the Guest Editor

Dear Colleagues,

The field of non-small cell lung cancer (NSCLC) has made significant advances over the last decade. This ranges from staging classification, pathological classification, early lung screening, cytotoxic chemotherapy and new targeted treatments that have transformed lung cancer treatment for metastatic disease with molecular biomarkers. We are now entering into the new exciting era of an immunotherapy approach using drugs that can prevent NSCLC cells from evading the immune system. The purpose of this special issue is to summarize and update fellow researchers as to the remarkable progress we have made for NSCLC therapies in the last several years. Both review papers and research papers are welcome.

Prof. Dr. Siow Ming Lee
Guest Editor

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases. In Scopus, papers published in Cancers in 2013 and 2014 have been cited 4.5 times, on average, in 2015 (SJR Scimago).

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 29 days after submission; acceptance to publication is undertaken in 6 days (median values for papers published in this journal in 2016).